title: Control of cardiovascular risk factors in the Veterans Affairs Diabetes Trial in advanced type 2 diabetes.
abstract: OBJECTIVE
  To present a status report on the Veterans Affairs Diabetes Trial (VADT), a multisite long-term study examining the effect of glucose control on cardiovascular (CV) complications in older patients with established, poorly controlled type 2 diabetes.
  
  
  METHODS
  We review the rationale, objectives, and design of the VADT and summarize the baseline data and the results achieved thus far.
  
  
  RESULTS
  The main objective of this 20-site, 1,792-patient study is to ascertain whether intensive glucose control can reduce major CV events in patients with difficult-to-control type 2 diabetes. The study design consists of a standard treatment arm and an intensive treatment arm, with a goal of 1.5% difference in hemoglobin A1c values between the two groups. The trial is now in its fifth year, with completion expected in December 2007. The planned glucose separation has been achieved and maintained to this point. Blood pressure and hemoglobin A1c levels have been reduced from baseline values, and established CV risk factors are within recommended ranges.
  
  
  CONCLUSIONS
  The current results of the VADT show that excellent control of glucose and CV risk factors can be achieved and maintained in the population studied. The results of these interventions on CV outcomes will ultimately have important implications for the clinical care of older patients with advanced type 2 diabetes.
authors.affiliation: Veterans Affairs Medical Center and Department of Medicine, University of Arizona, Phoenix, USA.
authors.forename: William C
authors.initials: WC
authors.lastname: Duckworth
authors.forename: Madeline
authors.initials: M
authors.lastname: McCarren
authors.forename: Carlos
authors.initials: C
authors.lastname: Abraira
mesh_terms: D001786:Blood Glucose / Q000032:analysis; D001794:Blood Pressure; D015992:Body Mass Index; D002318:Cardiovascular Diseases / Q000453:epidemiology / Q000517:prevention & control*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000150:complications* / Q000188:drug therapy*; D005260:Female; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D008055:Lipids / Q000097:blood; D008297:Male; D008875:Middle Aged; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D014481:United States; D014493:United States Department of Veterans Affairs
chemical_list: D001786:Blood Glucose; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D008055:Lipids